With analysts raising price targets ahead of key earnings reports, investors are watching American Express (NYSE: AXP), Deckers Outdoor (NYSE: DECK), and Biogen (NASDAQ: BIIB) closely for potential upside. Here’s why Wall Street’s outlook is improving and what could drive each company higher in the weeks ahead.
JP Morgan Turns Bullish on American Express
Unlike many competitors, American Express manages both the cardholder and merchant sides of each transaction. This allows the company to generate revenue from merchant fees, transaction processing, annual card fees, and interest income.
The company has also built a loyal customer base of higher-income consumers who tend to spend more and have lower default rates than the industry average. That premium customer mix has helped American Express consistently deliver strong financial performance, even during periods of economic uncertainty.
Confidence in the stock received another boost on July 13, when JP Morgan analyst Richard Shane upgraded American Express from Neutral to Overweight and raised his price target from $328 to $400. The sizable increase suggests the bank expects stronger earnings growth and continued resilience in consumer spending.
HSBC maintained its Hold rating but increased its price target from $312 to $329, adding to signs that Wall Street’s outlook is becoming more optimistic.
American Express reports its quarterly earnings on July 24. Strong spending trends, credit quality, and guidance for the remainder of the year will likely be key areas of focus.
Jefferies Bullish on Deckers
Jefferies analyst Blake Anderson upgraded the stock from Hold to Buy and raised his price target from $110 to $130.
Anderson previously maintained a cautious outlook. Earlier this year, he rated the stock Hold with a $105 target. Moving directly to a Buy rating signals that Jefferies believes the company’s growth prospects have strengthened significantly. Investors are likely expecting continued momentum from Hoka, international expansion, and healthy consumer demand despite ongoing concerns about discretionary spending.
Deckers is scheduled to report earnings on July 23, giving investors a clearer picture of whether the company’s growth story remains intact.
Truist Gets Bullish on Biogen
Biogen has long been recognized as one of the biotechnology industry’s leading companies, particularly in treatments for neurological diseases. Its portfolio includes established therapies for multiple sclerosis, including Tysabri and Tecfidera, along with Spinraza, a leading treatment for spinal muscular atrophy.
More recently, investor attention has shifted toward Leqembi, the Alzheimer’s treatment Biogen co-developed with Japanese pharmaceutical company Eisai. As one of the few approved therapies designed to slow the progression of early Alzheimer’s disease, Leqembi represents an important long-term growth opportunity for the company.
With that, Truist Securities analyst Danielle Brill upgraded Biogen from Hold to Buy while raising her price target from $190 to $235. RBC Capital Markets also raised its price target to $242 on July 7. Investors will be paying close attention to Biogen’s earnings report on July 29, looking for updates on Leqembi adoption, pipeline progress, and overall revenue growth.
What It Means for Investors
Analyst upgrades can serve as an important signal that Wall Street expects improving business performance or stronger earnings in the months ahead. While upgrades don’t guarantee future stock gains, they often reflect new information, changing market conditions, or greater confidence in a company’s growth prospects.
In the case of American Express, analysts are highlighting the company’s resilient premium customer base and consistent financial performance. For Deckers Outdoor, optimism centers on the continued strength of Hoka and Ugg, two brands that continue to outperform many competitors. Meanwhile, Biogen’s growing Alzheimer’s franchise is giving analysts renewed confidence in the company’s long-term growth story.
